RA Task Force Recommendations and the Use of Biologic Agents

May 12, 2010
RheumatologyNetwork Staff

(AUDIO) Treatment targets have helped improve outcomes in other areas of medicine. Now an international task force has developed recommendations for RA. In a series of four podcasts, Stephen A. Paget, MD, Chairman of the Division of Rheumatology at the Hospital for Special Surgery in New York and a Journal of Musculoskeletal Medicine editorial board member, will discuss the key points and implications regarding the use of biologic agents, managing RA comorbidities, future RA treatment, and health care reform. Part 1 focuses on the use of biologic agents.

Treatment Targets Set to Improve Patient Outcomes in RA

Treatment targets have helped improve outcomes in other areas of medicine. Now an international task force has developed recommendations for RA. In a series of four podcasts, Stephen A. Paget, MD, Chairman of the Division of Rheumatology at the Hospital for Special Surgery in New York and a Journal of Musculoskeletal Medicine editorial board member, will discuss the key points and implications regarding the use of biologic agents, managing RA comorbidities, future RA treatment, and health care reform. Part 1 focuses on the use of biologic agents.

Insights into how the development of treatment targets for RA will affect the use of biologic agents in the quest for disease remission are provided by Stephen A. Paget, MD, Chairman of the Division of Rheumatology at the Hospital for Special Surgery in New York.

RA Task Force Recommendations and the Use of Biologic Agents

 

Related Content:

Rheumatoid Arthritis